Kiniksa Pharmaceuticals (NASDAQ:KNSA) issued its earnings results on Monday. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.03, Fidelity Earnings reports.
Shares of Kiniksa Pharmaceuticals stock traded up $0.24 on Tuesday, hitting $11.23. The stock had a trading volume of 307 shares, compared to its average volume of 65,808. Kiniksa Pharmaceuticals has a one year low of $10.76 and a one year high of $32.88. The firm has a market cap of $621.95 million, a PE ratio of -3.20 and a beta of -1.56. The firm has a 50-day moving average of $13.12.
KNSA has been the topic of several recent analyst reports. ValuEngine upgraded shares of Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Kiniksa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 4th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Kiniksa Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $31.50.
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Further Reading: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.